Medicine Drop Shipper From India

Product Details:

Satnam Trading Company                                    Nagpur - INDIA
Company Profile
 
Introduction:
 
We would like to introduce ourselves as exporters of pharmaceutical products based at Nagpur, Maharashtra - INDIA dealing in all kinds of human and pet medications through drop shipment and bulk shipment.
 
Our endeavor is to become the most trusted and respected pharmaceutical dispensing agency around the globe, to achieve this we have a strong belief that we need to be fair and ethical to all our stake holders i.e. business partners, regulatory bodies, end users and employees. In short; our aim is to become the most obvious choice for all.
 
Key Features:
 
In the many years we have forayed ourselves into drop shipment and bulk shipment business of pharmaceuticals. The key features of our business are as below:
 
Ø  Products of MNCs and leading Indian companies
Ø  Special prices for oncology, HIV, ED products and others
Ø  Fastest and safest delivery of medication across the globe
Ø  Quality & hygiene packaging as per international standards
 
Products:
 
We deal in all types of pharmaceutical products especially those which belong to MNCs and leading Indian brands. Our list contains about 1500 products of repute, which are regularly supplied to our customers across the globe.
 
Shipping Process: 
 
The business orders received to us are executed within few hours and the shipment is dispatched within 24 hours in case of drop shipments. The entire process is seamless which includes courier booking, customs clearance, loading of parcels to the international flights.
 
In the entire process of shipping, the packaging and safety of drugs is as per the international standards which are not negotiable at our end.
 
 
 
Back End Resources:
 
We have an air-conditioned office premise of about 500 square feet which is fully automated with the latest equipment. All the departments have a separate working space. Exclusive arrangement has been made for the storage and dispensing areas.  
 
Future Plans:
 
The promoters are committed to take the company to greater heights by going in for expansion in near future or as and when the opportunity comes.
 
Relevant Licenses / Compliances:
 
Our company has a valid license to operate from Food and Drug Administration (FDA). We fully comply with the norms laid down by Additional Drug Controller (ADC). We meet the entire rules and regulations pertaining to Income Tax, GST Tax, etc. Our company works within the framework of DGFT (Director General of Foreign Trade) and strictly works under RBI (Reserve Bank of India) guidelines.
 
 
 
 

Product Details:

Additional Information:

• Item Code: POSTSERVICE
• Production Capacity: 100000
• Delivery Time: 8-12 DAYS
• Packaging Details: BOX PACKING AND ENVELOP PACKING

Product Details:

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.
The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Miami-based company Ridgeback Biotherapeutics, who later partnered with Merck & Co. to develop the drug further.
Safety controversyIn April 2020, a whistleblower complaint by former Head of US Biomedical Advanced Research and Development Authority (BARDA) Rick Bright revealed concerns over providing funding for the further development of molnupiravir due to similar drugs having mutagenic (DNA damaging) properties.[3] A previous company, Pharmasset, that had investigated the drug's active ingredient had abandoned it. These claims were denied by George Painter, CEO of DRIVE, noting that toxicity studies on molnupiravir had been carried out and data provided to regulators in the US and UK, who permitted safety studies in humans to move forward in the spring of 2020. Also at this time, DRIVE and Ridgeback Biotherapeutics stated they planned future safety studies in animals.

Additional Information:

• Delivery Time: 7 TO 15 DAYS
• Packaging Details: Finished Product